Search

Your search keyword '"Beydoun S"' showing total 142 results

Search Constraints

Start Over You searched for: Author "Beydoun S" Remove constraint Author: "Beydoun S"
142 results on '"Beydoun S"'

Search Results

2. P277 Long-term safety, tolerability, and efficacy of Efgartigimod in patients with Generalized Myasthenia Gravis: concluding analyses from the ADAPT+ study

3. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial

5. ‘Minimal symptom expression’ in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab

6. Consistent improvement with eculizumab across muscle groups in myasthenia gravis

7. Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studies

8. Eculizumab in refractory generalized myasthenia gravis previously treated with rituximab:subgroup analysis of REGAIN and its extension study

9. Eculizumab Improves Fatigue in Refractory Generalized Myasthenia Gravis

10. ‘Minimal symptom expression’ in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab

11. Minimal manifestation status and prednisone withdrawal in the MGTX trial

12. OP0090 EFFICACY OF SUBCUTANEOUS TANEZUMAB FOR THE TREATMENT OF CHRONIC LOW BACK PAIN: AN ANALYSIS OF BRIEF PAIN INVENTORY-SHORT FORM SCORES FROM A 56-WEEK, RANDOMIZED, PLACEBO- AND TRAMADOL-CONTROLLED, PHASE 3 TRIAL

15. Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis

16. Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP: PATH extension study

17. Correction to: Eculizumab improves fatigue in refractory generalized myasthenia gravis (Quality of Life Research, (2019), 28, 8, (2247-2254), 10.1007/s11136-019-02148-2)

19. Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre-randomization phase of the Polyneuropathy And Treatment with Hizentra study

20. Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP PATH extension study

21. Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studies

22. Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre-randomization phase of the Polyneuropathy And Treatment with Hizentra study

23. Optimal feedback design for uncertain systems: a time-domain fixed-point approach in L infinity

25. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial

26. Randomized Trial of Thymectomy in Myasthenia Gravis

27. Randomized trial of thymectomy in myasthenia gravis

28. Randomized trial of thymectomy in myasthenia gravis

29. P.043 Long-term safety, tolerability, and efficacy of efgartigimod in patients with Generalized Myasthenia Gravis: concluding analyses from ADAPT+

30. Evaluation of surgical staples in cesarean section

31. Anticonvulsants

38. Malaria in pregnancy.

45. Cervicothoracic spinal cord and pontomedullary injury secondary to high-voltage electrocution: a case report

46. Emotional stress as a trigger of myasthenic crisis and concomitant takotsubo cardiomyopathy: a case report

47. Amyotrophic lateral sclerosis-motor neuron disease, monoclonal gammopathy, hyperparathyroidism, and B12 deficiency: case report and review of the literature

50. Ifosfamide encephalopathy

Catalog

Books, media, physical & digital resources